Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Receivables - Net (2017 - 2025)

Historic Receivables - Net for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $5.6 million.

  • Innate Pharma's Receivables - Net fell 7370.96% to $5.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.6 million, marking a year-over-year decrease of 7370.96%. This contributed to the annual value of $5.3 million for FY2024, which is 9253.07% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Receivables - Net is $5.6 million, which was down 7370.96% from $5.3 million recorded in Q4 2024.
  • Innate Pharma's Receivables - Net's 5-year high stood at $71.1 million during Q4 2023, with a 5-year trough of $5.3 million in Q4 2024.
  • Its 5-year average for Receivables - Net is $39.8 million, with a median of $53.5 million in 2022.
  • Its Receivables - Net has fluctuated over the past 5 years, first plummeted by 9965.93% in 2021, then soared by 15392.46% in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's Receivables - Net stood at $21.1 million in 2021, then surged by 153.92% to $53.5 million in 2022, then skyrocketed by 32.94% to $71.1 million in 2023, then crashed by 92.53% to $5.3 million in 2024, then increased by 5.48% to $5.6 million in 2025.
  • Its Receivables - Net stands at $5.6 million for Q2 2025, versus $5.3 million for Q4 2024 and $21.3 million for Q2 2024.